Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00458
|
|||||
| Drug Name |
Pantoprazole
|
|||||
| Synonyms |
5-(Difluoromethoxy)-2-(((3,4-dimethoxy-2-pyridyl)methyl)sulfinyl)benzimidazole; 5-(difluoromethoxy)-2-{[(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole; 6-(difluoromethoxy)-2-[(3,4-dimethoxypyridin-2-yl)methylsulfinyl]-1H-benzimidazole; Astropan; Astropan (TN); BY 1023; BY-1023; Controloc (TN); Inipomp (TN); Pantecta (TN); Pantoloc (TN); Pantopan (TN); Pantoprazol; Pantoprazol [INN-Spanish]; Pantoprazole (USAN/INN); Pantoprazole Na; Pantoprazole Sodium; Pantoprazole [USAN:BAN:INN]; Pantoprazolum; Pantoprazolum [INN-Latin]; Pantoprozole; Pantor; Pantor (TN); Pantotab (TN); Pantozol; Pantozol (TN); Protium; Protium (TN); Protonix; Protonix (TN); Protonix IV; SK&F 96022; SK&F-96022; SK-96022; SKF-96022; Somac; Somac (TN); Ulcepraz (TN)
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Gastroesophageal reflux disease [ICD11:DA22] | Approved | [1] | |||
| Therapeutic Class |
Antiulcer Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C16H15F2N3O4S
|
|||||
| Canonical SMILES |
COC1=C(C(=NC=C1)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC(F)F)OC
|
|||||
| InChI |
InChI=1S/C16H15F2N3O4S/c1-23-13-5-6-19-12(14(13)24-2)8-26(22)16-20-10-4-3-9(25-15(17)18)7-11(10)21-16/h3-7,15H,8H2,1-2H3,(H,20,21)
|
|||||
| InChIKey |
IQPSEEYGBUAQFF-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 102625-70-7
|
|||||
| Pharmaceutical Properties | Molecular Weight | 383.4 | Topological Polar Surface Area | 106 | ||
| Heavy Atom Count | 26 | Rotatable Bond Count | 7 | |||
| Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 9 | |||
| XLogP |
2.4
|
|||||
| PubChem CID | ||||||
| PubChem SID |
103557047
,104098729
,104178843
,104307108
,118318262
,125336751
,126525315
,126630995
,126658184
,126670715
,128206212
,131293114
,134338012
,135028043
,135692424
,136948045
,137088311
,137175473
,13970
,141641906
,141641915
,142318542
,14902603
,17183107
,17398288
,26526442
,26612946
,26749082
,26749083
,29223767
,46504622
,47959868
,48416375
,49830151
,49882833
,50107519
,50432438
,53788377
,56394975
,57322393
,6752164
,7980248
,81040904
,85789648
,91011863
,92124724
,92307944
,92309139
,92711310
,93166161
|
|||||
| ChEBI ID |
ChEBI:7915
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [2] | |
| P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [3] | ||
| References | ||||||
| 1 | Pantoprazole was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. Cancer Res. 2004 Aug 15;64(16):5804-11. | |||||
| 3 | A novel screening strategy to identify ABCB1 substrates and inhibitors. Naunyn Schmiedebergs Arch Pharmacol. 2009 Jan;379(1):11-26. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.